Phathom Pharmaceuticals (PHAT) officer surrenders 1,555 for tax withholding

Rhea-AI Filing Summary

Phathom Pharmaceuticals, Inc. principal accounting officer Robert Charles Breedlove reported an F-code tax-withholding disposition of 1,555 shares of common stock on July 14, 2026, at $11.035 per share, surrendering shares underlying restricted stock units to the issuer to satisfy its tax withholding obligation. After this event, he holds 59,925.0000 shares directly and 6,945.4000 shares indirectly through a 401(k) plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Breedlove Robert Charles

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,555	$11.035	$17K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 59,925 shares (Direct); Common Stock — 6,945.4 shares (Indirect, By 401(k))

Footnotes (1)

1. [object Object]

Key Figures

Tax-withholding shares: 1555.0000 shares Tax-withholding price: $11.0350 per share Direct holdings after transaction: 59925.0000 shares +1 more

4 metrics

Tax-withholding shares 1555.0000 shares Shares underlying RSUs surrendered on July 14, 2026 to satisfy tax withholding

Tax-withholding price $11.0350 per share Value used for the F-code tax-withholding disposition of 1,555.0000 shares

Direct holdings after transaction 59925.0000 shares Common stock directly held by Breedlove following the July 14, 2026 event

Indirect 401(k) holdings 6945.4000 shares Common stock held indirectly through a 401(k) plan as reported in the filing

Key Terms

restricted stock units, tax withholding obligation, indirect ownership, 401(k)

4 terms

restricted stock units financial

"shares underlying the restricted stock units that were surrendered"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligation financial

"in satisfaction of the Issuer's tax withholding obligation"

indirect ownership financial

"direct_or_indirect: I, ownership_type: indirect"

401(k) financial

"nature_of_ownership: By 401(k)"

A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:31 PM Accepted by SEC EDGAR 07/16/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What insider transaction did Phathom Pharmaceuticals (PHAT) report for Robert Charles Breedlove?

Phathom’s principal accounting officer Robert Charles Breedlove reported an F-code tax-withholding disposition, surrendering shares underlying restricted stock units to the issuer to cover its tax withholding obligation on July 14, 2026.

How many PHAT shares were surrendered for tax withholding and at what price?

Breedlove surrendered 1,555.0000 shares of Phathom common stock at $11.0350 per share. These shares represented restricted stock units delivered to the issuer specifically to satisfy its tax withholding obligation, not an open-market sale.

How many Phathom (PHAT) shares does Robert Charles Breedlove hold after the reported transaction?

Following the tax-withholding disposition, Breedlove holds 59,925.0000 Phathom common shares directly and 6,945.4000 shares indirectly through a 401(k) plan, as reported in the ownership balances after the July 14, 2026 event.

Was the Phathom (PHAT) insider transaction an open-market sale of shares?

No. The filing describes an F-code tax-withholding disposition, where shares underlying restricted stock units were surrendered to Phathom to satisfy its tax withholding obligation, rather than being sold in an open-market transaction.

What indirect Phathom (PHAT) shareholdings did Robert Charles Breedlove report?

Breedlove reported 6,945.4000 Phathom common shares held indirectly by 401(k). This entry reflects shares credited to a 401(k) plan account and is classified in the filing as indirect ownership rather than a new transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breedlove Robert Charles

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/14/2026		F(1)		1,555	D	$11.035	59,925	D
Common Stock								6,945.4	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

	/s/ Robert Charles Breedlove	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)